The Priority Review

Tag

Approvals

1 story

  1. Approvals

    FDA expands Anktiva indication to high-grade papillary bladder cancer

    On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumors. The agency extrapolated from earlier data in patients with carcinoma in situ.